<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>bootstrap validation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/bootstrap-validation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 04 Oct 2026 19:54:22 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>bootstrap validation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>PET Scan Data Joins Clinical Factors to Predict Relapse in MALT Lymphoma</title>
		<link>https://bioengineer.org/pet-scan-data-joins-clinical-factors-to-predict-relapse-in-malt-lymphoma/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 04 Oct 2026 19:54:22 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[bootstrap validation]]></category>
		<category><![CDATA[Cox regression]]></category>
		<category><![CDATA[FDG PET/CT]]></category>
		<category><![CDATA[Ki-67 index]]></category>
		<category><![CDATA[LASSO regression]]></category>
		<category><![CDATA[MALT lymphoma]]></category>
		<category><![CDATA[MALT-IPI]]></category>
		<category><![CDATA[nomogram]]></category>
		<category><![CDATA[nuclear medicine]]></category>
		<category><![CDATA[prognosis]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<category><![CDATA[SUVmax]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=401242</guid>

					<description><![CDATA[Researchers in Wuhan have built a prognostic nomogram that combines FDG PET/CT metabolic imaging with clinical and pathological variables to predict progression-free survival in MALT lymphoma, achieving moderate validated accuracy and refining risk within the intermediate-risk group.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">401242</post-id>	</item>
	</channel>
</rss>
